|
rs2585428
|
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
<b>Aim:</b> rs2585428 and rs4809960 polymorphisms were significantly associated with overall cancer risk, but there is no evidence regarding the overall colorectal cancer (CRC) risk.
|
31802707 |
2020 |
|
rs4809960
|
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
<b>Conclusion:</b> Our findings indicate that the <i>CYP24A1</i> rs4809960 polymorphism decreased the risk of CRC in the studied population.
|
31802707 |
2020 |
|
rs7025417
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusion:</b> These data suggest that the rs7025417 CC genotype may downregulate <i>IL-33</i> mRNA and subsequently reduce the risk of CRC.
|
31140826 |
2019 |
|
rs4796672
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusion:</b> We have identified three SNPs associated with CRC risk and demonstrated a gender specificity of rs590352 and rs4796672.
|
31797724 |
2020 |
|
rs590352
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusion:</b> We have identified three SNPs associated with CRC risk and demonstrated a gender specificity of rs590352 and rs4796672.
|
31797724 |
2020 |
|
rs2632159
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusion:</b><i>PCAT1</i> rs2632159 SNP could be a biomarker for CRC risk.
|
31253700 |
2019 |
|
rs8720
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma</span> (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
|
rs7960917
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
|
rs11614913
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Results:</b> Three SNPs were significantly associated with survival of patients with colorectal cancer after correction for multiple testing, and two of the SNPs (<i>hsa-mir-196a-2</i> rs11614913 and <i>U85</i> rs714775) remained significant in multivariate analyses.
|
29483812 |
2018 |
|
rs714775
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Results:</b> Three SNPs were significantly associated with survival of patients with colorectal cancer after correction for multiple testing, and two of the SNPs (<i>hsa-mir-196a-2</i> rs11614913 and <i>U85</i> rs714775) remained significant in multivariate analyses.
|
29483812 |
2018 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due to feedback reactivation of receptor tyrosine kinase signaling.
|
28951457 |
2017 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due to feedback reactivation of receptor tyrosine kinase signaling.
|
28951457 |
2017 |
|
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due to feedback reactivation of receptor tyrosine kinase signaling.
|
28951457 |
2017 |
|
rs6983267
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>CCAT2</i> rs6983267 was associated with the risk of CRC per</span> se (<i>p</i> < 0.01).
|
30841568 |
2019 |
|
rs266729
|
|
Colorectal Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
<i>Conclusions</i>: Our findings show that APN rs266729 G/C polymorphism is associated with lower APN levels in CRC patients, indicating that decreased circulating levels of APN may be a determinant risk factor for CRC in MetS patients.
|
28529612 |
2017 |
|
rs664589
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>In vitro</i> and <i>in vivo</i> experiments showed that the rs664589 C to G mutation facilitated carcinogenesis and metastasis of colorectal cancer.
|
31311811 |
2019 |
|
rs266729
|
|
Colorectal Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
<i>Results</i>: We found that CRC patients (N=75) with genotype rs266729G/C or carriers of G allele were associated with a significantly increased risk of MetS development (OR =2.9) compared to those with CC genotype (N=30).
|
28529612 |
2017 |
|
rs833061
|
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
<i>VEGFA</i> rs833061 polymorphism is significantly associated with the therapeutic efficiency of bevacizumab in CRC patients.
|
29285265 |
2017 |
|
rs1217691063
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Colorectal cancer and the methylenetetrahydrofolate reductase 677C -> T and methionine synthase 2756A -> G polymorphisms: a study of 2,168 case-control pairs from the JANUS cohort.
|
15598777 |
2004 |
|
rs1217691063
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Colo-rectal cancer risk is decreased in subjects homozygous for a common variant (C677T) of the gene coding for this enzyme, suggesting that DNA synthesis and repair may be 'enhanced' in these individuals.
|
15831129 |
2004 |
|
rs1202168
|
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
CRC risk associated with ever MHT use as well as with duration was significantly modified by rs1202168 in the transporter gene ABCB1 (P interaction=0.04).
|
21490239 |
2011 |
|
rs121913338
|
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Colorectal cancers with BRAF D594G mutations exhibit similar clinicopathological features, microsatellite instability status, and prognosis as those with BRAF wild-type.
|
27404270 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Colorectal cancer (CRC) is one of the most common cancers worldwide, with 8-10% of these tumours presenting a BRAF (V600E) mutation.
|
30087414 |
2018 |